QLT INC. Patent applications |
Patent application number | Title | Published |
20150038582 | THERAPEUTIC REGIMENS AND METHODS FOR IMPROVING VISUAL FUNCTION IN VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY - Therapeutic regimes for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising administering the synthetic retinal derivative as a divided dose over 2-7 days then providing a resting period of 7-28 days after which the second dose of the synthetic retinal derivative is administered. Preferred synthetic retinal derivatives are 9- or 11-cis-retinyl esters. Disorders associated with deficiency in endogenously produced 11-cis retinal include retinitis pigmentosa and Leber congenital amaurosis. | 02-05-2015 |
20140094484 | SUSTAINED DELIVERY FORMULATIONS OF RAPAMYCIN COMPOUNDS - The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative. | 04-03-2014 |
20130101658 | DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM - A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive. | 04-25-2013 |
20120318281 | LACRIMAL IMPLANTS AND RELATED METHODS - Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed. | 12-20-2012 |
20120277694 | PUNCTAL PLUG WITH ACTIVE AGENT - A punctal plug for insertion through a punctal aperture of an eye. The punctal plug includes a stem configured to be inserted into the punctal aperture and along a canaliculus of the eye, a stopper connected to one end of the stem, the stopper configured to seat against the punctal aperture, and a topical prostaglandin. The stem and the stopper are made from a porous or absorbent material, and wherein the material is saturated with the topical prostaglandin. | 11-01-2012 |
20120245682 | SURFACE TREATED IMPLANTABLE ARTICLES AND RELATED METHODS - Surface treated implantable articles and related methods are disclosed. The surface treated implantable articles can be substantially flash-free, include one or more rounded edges, or include an enhanced optical clarity, one or all of which can be produced by polishing. The polishing can include causing the implantable articles to be repeatedly impacted with polishing media when the articles are swelled to an enlarged state. The polishing process can be particularly useful for smoothing lacrimal implants insertable in a lacrimal canaliculus. | 09-27-2012 |
20120245539 | LACRIMAL IMPLANTS INCLUDING SPLIT AND INSERTABLE DRUG CORE - Lacrimal implants providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body, including first and second portions, extending from a proximal end of the first portion to a distal end of the second portion. The second portion includes a retention projection. The implant body can also include a cavity longitudinally extending from the proximal end of the first portion toward the second portion, wherein the cavity is shaped and sized to receive an insertable actuator, and wherein the retention projection is configured to bias outward or change orientation when the insertable actuator is seated within the cavity. | 09-27-2012 |
20120203162 | METHOD FOR TREATING NEOVASCULARIZATION - The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV). | 08-09-2012 |
20120187594 | DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues. | 07-26-2012 |
20120178806 | PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE - Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans. | 07-12-2012 |
20120041356 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE - The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone. | 02-16-2012 |
20110276131 | NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR DRUG THERAPY - An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen. | 11-10-2011 |
20110257266 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated - Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others. | 10-20-2011 |
20110202020 | TREATMENT MEDIUM DELIVERY DEVICE AND METHODS FOR DELIVERY OF SUCH TREATMENT MEDIUMS TO THE EYE USING SUCH A DELIVERY DEVICE - A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device. | 08-18-2011 |
20100204317 | METHODS OF TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS - This invention is directed to the use of TOFA in the treatment of acne and other dermatological disorders. This invention is also directed to pharmaceutical compositions comprising TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration. | 08-12-2010 |
20100179218 | OCULOSELECTIVE DRUGS AND PRODRUGS - Compounds of the following formula are disclosed: | 07-15-2010 |
20100056982 | Photodynamic therapy for the treatment of acne - The present method involves the photodynamic treatment of acne vulgaris. The method involves the topical administration of a photosensitizer composition comprising hydrophobic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOLâ„¢ to acne-affected skin and subsequent exposure of that skin to energy of a wavelength of activating the photosensitizer. | 03-04-2010 |